✦ LIBER ✦

Optimal Response-Adaptive Designs for Continuous Responses in Phase III Trials

✍ Scribed by Atanu Biswas; Rahul Bhattachary; Lanju Zhang

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 191 KB
Volume: 49
Category: Article
ISSN: 0323-3847
DOI: 10.1002/bimj.200610358

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Optimal Response-Adaptive Designs for No

Optimal Response-Adaptive Designs for Normal Responses

✍ Atanu Biswas; Rahul Bhattacharya 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

## Abstract Most of the available response‐adaptive designs in phase III clinical trial set up are not from any optimal consideration. An optimal design for binary responses is given by Rosenberger et al. (2001) and an optimal design for continuous responses is provided by Biswas and Mandal (2004).

Adaptive design improvements in the cont

Adaptive design improvements in the continual reassessment method for phase I studies

✍ Julie M. Heyd; Bradley P. Carlin 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

The continual reassessment method (CRM) enables full and e$cient use of all data and prior information available in a phase I study. However, despite a number of recent enhancements to the method, its acceptance in actual clinical practice has been hampered by several practical di$culties. In this p

Critical Assessment of the C-Optimality

Critical Assessment of the C-Optimality Design Criteria for Estimating the Median Effective Dose in Quantal Dose-Response Curves

✍ Volker Guiard; Uwe Pichlmeier 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 402 KB 👁 1 views

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ W. Rigby; H.-P. Tony; K. Oelke; B. Combe; A. Laster; C. A. von Muhlen; E. Fishel 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ P. P. Tak; P. J. Mease; M. C. Genovese; J. Kremer; B. Haraoui; Y. Tanaka; C. O. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views